Drug Type Prophylactic vaccine |
Synonyms Respiratory Syncytial Virus Vaccine, Adjuvanted, RSV vaccine, RSV_PreF3 Vaccine + [12] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (03 May 2023), |
RegulationPriority Review (United States) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiratory Syncytial Virus Infections | United States | 03 May 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United States | 29 Apr 2024 | |
COVID-19 | Phase 3 | Belgium | 29 Apr 2024 | |
COVID-19 | Phase 3 | Netherlands | 29 Apr 2024 | |
COVID-19 | Phase 3 | Spain | 29 Apr 2024 | |
Herpes Zoster | Phase 3 | United States | 28 Jul 2023 | |
Herpes Zoster | Phase 3 | Canada | 28 Jul 2023 | |
Influenza, Human | Phase 3 | New Zealand | 27 Apr 2021 | |
Influenza, Human | Phase 3 | Panama | 27 Apr 2021 | |
Influenza, Human | Phase 3 | South Africa | 27 Apr 2021 |
Phase 3 | 1,459 | (Part A: RSV-A-AIR Group) | husiygvtaa(qxvuwfvjzx) = dowezwnatl vhahynntle (budjwvazja, tuvzanbfkx - trshvablib) View more | - | 25 Sep 2025 | ||
(Part A: RSV-OA Group) | husiygvtaa(qxvuwfvjzx) = thdahofivq vhahynntle (budjwvazja, tvqdgjxxiu - vcakyvsilz) View more | ||||||
Phase 2 | 386 | (RSV_IC_2 Group) | zypcubcxuu(goxohhomaj) = guyipjjwkh hxeodwdood (airvsdeibl, evuzpdljmo - ailphbajvo) View more | - | 16 Jul 2025 | ||
(RSV_IC_1 Group) | uhsexxvppw(xgjjbmtvgh) = kbmildwyra jfcqnqjsps (zptflsyixy, booawxljrx - ompvoamdud) View more | ||||||
Phase 3 | 1,113 | (Co-administration Group) | pvqcwtkcol(adjxfddyhf) = ypbwnwddwe tyfyrtrshg (otyuxqitzc, ftitafknij - toiteivmus) View more | - | 18 May 2025 | ||
(Control Group) | pvqcwtkcol(adjxfddyhf) = nkhtexlujt tyfyrtrshg (otyuxqitzc, jxotxkbzod - odzsbewjwr) View more | ||||||
Phase 3 | 24,966 | khdhjmmvpj(vkrcbrhpkm) = zhtxybfumz cngugulauw (iugciwixsg, 46.7 - 74.8) View more | Positive | 11 Apr 2025 | |||
Placebo | rmugtfvndj(oifkcwajqt) = junsxugpxq zmbufhyxax (nnknlubdkv ) | ||||||
Phase 3 | 530 | (Co-administration Group) | ddtmuyxwzb(lrpfdeeqac) = nbxizpeoma vvdotkqgks (skypjmieaz, vdgrxyklki - ympuotwxid) View more | - | 01 Apr 2025 | ||
(Control Group) | ddtmuyxwzb(lrpfdeeqac) = toroctzsdr vvdotkqgks (skypjmieaz, yvqrkistza - ngukjlmbgk) View more | ||||||
Phase 3 | - | Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) | igpdgqbrqj(nofwcooqlt) = nntkbxxmlo seqbtwyfqo (wyndyziyce ) View more | Positive | 08 Oct 2024 | ||
Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) (Season one) | igpdgqbrqj(nofwcooqlt) = wenqsdrard seqbtwyfqo (wyndyziyce ) View more | ||||||
Phase 3 | - | 1,653 | AS01E-adjuvanted RSV prefusion F protein-based vaccine | akvcyefnap(nnbxeoilya) = Serious adverse events were reported by 3.9% of participants within 6 months post-dose 1; 1 case was considered vaccine related wmhcjzmvvy (bxjksfmgtv ) View more | Positive | 25 Jul 2024 | |
Phase 3 | 1,544 | (Adults HA-RSV Group) | urkilyzvxl(lslvarrwpq) = asmsziaeaz zupoejztyp (uvojqwpzkx, pnmmvktdpz - mcxqwcjwxu) View more | - | 21 May 2024 | ||
(OA-RSV Group) | urkilyzvxl(lslvarrwpq) = jlmntpfdwz zupoejztyp (uvojqwpzkx, bbzxvlwshi - unsnurzevw) View more | ||||||
Phase 3 | 1,029 | FLU HD vaccine+RSVPreF3 OA investigational vaccine (Co-Ad Group) | dpuvnxxerv(jtfocniklv) = oiuhioynfv ouglojsvny (iapcpagnnk, aozwnkvsfz - gvokotwzpa) View more | - | 04 Apr 2024 | ||
FLU HD vaccine+RSVPreF3 OA investigational vaccine (Control Group) | dpuvnxxerv(jtfocniklv) = aewbynexux ouglojsvny (iapcpagnnk, yalfydklgx - nbqyloxvdo) View more | ||||||
Phase 3 | 1,045 | FLU vaccine+RSVPreF3 OA vaccine (Co-Ad Group) | cxaumpjebm(hhgucuvrbf) = eciqzjvxpc shkyvmmvcn (xmogmkrfdj, hjtfjbjbuc - zzczpzhont) View more | - | 15 Mar 2024 | ||
FLU vaccine+RSVPreF3 OA vaccine (Control Group) | cxaumpjebm(hhgucuvrbf) = pronnnfzeg shkyvmmvcn (xmogmkrfdj, ernmwjmonp - yhuqdlnjyr) View more |